Revised: 31 May 2019

Medicines

	Medsafe Product Detail
		File ref: TT50-10037

Composition

Production

Packaging

Indications

Tecentriq as monotherapy is indicated as adjuvant treatment following resection and platinum-based chemotherapy for patients with stage II to IIIA* non-small cell lung cancer (NSCLC) whose tumours have PD-L1 expression on greater then or equal to 1% of tumour cells (TC).
* According to American Joint Committee on Cancer [7th edition]

Tecentriq, in combination with nab-paclitaxel and carboplatin, is indicated for first-line treatment of patients with metastatic non-squamous NSCLC who do not have tumour EGFR or ALK genomic aberrations.

Tecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) after prior chemotherapy.

Tecentriq, in combination with paclitaxel and carboplatin, is indicated for the first-line treatment of patients with metastatic non-squamous NSCLC who do not have tumour EGFR or ALK genomic aberrations and whose tumours have PD-L1 expression greater than or equal to 1%.

Tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated for the first-line treatment of patients with metastatic non-squamous non-small cell lung cancer (NSCLC). In patients with EGFR mutant or ALK--positive NSCLC, Tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated only after failure of appropriate targeted therapies.

Tecentriq as monotherapy is indicated for the first-line treatment of adults with metastatic NSCLC whose tumours have high PD-L1 expression (PD-L1 stained greater than or equal to  50% of tumour cells [TC greater than or equal to  50%] or PD-L1 stained tumour-infiltrating immune cells [IC] covering greater than or equal to 10% of the tumour area [IC greater than or equal to  10%]) as determined by a validated test, and who do not have EGFR or ALK genomic tumour aberrations.

Tecentriq is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (UC) who:
- are considered cisplatin ineligible and whose tumours have a PD-L1 expression greater than or equal to 5%, or
- have disease progression during or following platinum-containing chemotherapy, or
- have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.

Tecentriq, in combination with nab-paclitaxel, is indicated for the treatment of patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) whose tumours have PD-L1 expression greater than or equal to 1%, and who have not received prior chemotherapy for metastatic disease.

Tecentriq, in combination with carboplatin and etoposide, is indicated for the first-line treatment of patients with extensive-stage small cell lung cancer (ES-SCLC).

Tecentriq, in combination with bevacizumab, is indicated for the treatment of patients with unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy.

Latest Regulatory Activity